ATP7A and liver cancer: By analyzing liver cancer patients receiving sorafenib, some researchers found that patients with high ATP7A expression had a longer overall survival (OS), indicating that ATP7A can improve the therapeutic effect of sorafenib in liver cancer; that is, high ATP7A indirectly promotes ferroptosis in liver cancer [22].